Philip Morris International (PMI) achieved positive results in 2024, driven by the expansion of its nicotine pouch brand Zyn as 2023’s demand acceleration continued alongside Iqos growth momentum.
In a landmark move last month, the US Food and Drug Administration (FDA) approved the marketing of 20 Zyn nicotine pouch products, marking the first such approval through its premarket tobacco product application (PMTA) process. This decision includes flavoured options like cinnamon, citrus and coffee, in 3 mg and 6 mg nicotine strengths. The authorisation supports harm-reduction alternatives, while imposing strict marketing restrictions to prevent youth exposure.
